Literature DB >> 7580474

Dornase alfa for cystic fibrosis.

G Robert, A Stevens, D Colin-Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7580474      PMCID： PMC2550832          DOI： 10.1136/bmj.311.7008.813

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  Respiratory medicine.

Authors:  R M du Bois
Journal:  BMJ       Date:  1995-06-17

2.  Dornase alfa for cystic fibrosis. Patients should not be denied a safe, effective treatment.

Authors:  A Bush; M E Hodson; D M Geddes; M Rosenthal; R Dinwiddie; C Wallis; D E Stableforth; S P Conway; J M Littlewood
Journal:  BMJ       Date:  1995-06-10

3.  Evolution of therapy for cystic fibrosis.

Authors:  P B Davis
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

4.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245
  4 in total
  1 in total

Review 1.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.